LifeStance Health Group (NASDAQ:LFST) Earns Overweight Rating from Morgan Stanley

Morgan Stanley reaffirmed their overweight rating on shares of LifeStance Health Group (NASDAQ:LFST) in a research report released on Monday, Benzinga reports. The firm currently has a $10.00 target price on the stock.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group boosted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a buy rating in a report on Wednesday, March 6th. Barclays lifted their price target on LifeStance Health Group from $7.00 to $8.00 and gave the stock an underweight rating in a research report on Thursday, February 29th. Finally, The Goldman Sachs Group lifted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the stock a neutral rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $8.83.

LifeStance Health Group Stock Performance

LFST opened at $5.87 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.11. The company has a market cap of $2.23 billion, a PE ratio of -11.51 and a beta of 1.34. The stock has a 50-day moving average of $6.48 and a 200-day moving average of $6.54. LifeStance Health Group has a 52-week low of $4.74 and a 52-week high of $9.59.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. The company had revenue of $280.60 million during the quarter, compared to analyst estimates of $263.14 million. As a group, equities research analysts forecast that LifeStance Health Group will post -0.3 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Kevin Michael Mullins sold 115,136 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $8.02, for a total transaction of $923,390.72. Following the sale, the insider now directly owns 4,575,480 shares in the company, valued at $36,695,349.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other LifeStance Health Group news, insider Paula Cipollone sold 13,996 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $6.93, for a total value of $96,992.28. Following the sale, the insider now directly owns 293,562 shares in the company, valued at $2,034,384.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin Michael Mullins sold 115,136 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the completion of the sale, the insider now owns 4,575,480 shares in the company, valued at $36,695,349.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 245,463 shares of company stock worth $1,786,868. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently bought and sold shares of LFST. SG Americas Securities LLC acquired a new position in LifeStance Health Group in the third quarter worth $206,000. Brown Advisory Inc. acquired a new position in LifeStance Health Group in the third quarter worth $28,140,000. WESPAC Advisors LLC acquired a new position in shares of LifeStance Health Group during the third quarter valued at $90,000. Jennison Associates LLC lifted its stake in shares of LifeStance Health Group by 35.4% during the third quarter. Jennison Associates LLC now owns 2,046,358 shares of the company’s stock valued at $14,058,000 after acquiring an additional 535,358 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of LifeStance Health Group by 4.5% during the third quarter. Principal Financial Group Inc. now owns 3,895,887 shares of the company’s stock valued at $26,765,000 after acquiring an additional 168,091 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.